Is it safe to take Bitovil/Bikernoprenol tablets for a long time?

Biktarvy is a first-line compound preparation widely used in the treatment of HIV infection (AIDS). It consists of three ingredients: bictegravir sodium (bictegravir), emtricitabine and tenofovir alafenamide (TAF). The original intention of its design is to simplify antiviral treatment regimens and achieve the goal of maintaining effective viral suppression with one tablet per day. Overseas studies and guidelines have unanimously pointed out that Bikeren Prenol Tablets exhibit high tolerability and safety in long-term use.

For HIV patients, treatment needs to be continued throughout life, so whether the drug can be taken safely for a long time is a core issue. Bicenavir tablets are pharmacokinetically stable and have better kidney and bone safety than early tenofovir preparations. At the same time, its integrase inhibitor has a higher resistance barrier than ctegravir, reducing the risk of drug resistance. This means that even if it is taken for a long time, treatment failure due to viral mutations is not likely to occur, which is of great value in clinical applications.

From a safety perspective, most of the common adverse reactions of Bikernprenamide tablets are mild, such as mild headache, fatigue or gastrointestinal discomfort, which usually resolve on their own after a period of adaptation. Compared with other similar drugs, its impact on liver and kidney function is generally controllable. Doctors generally recommend regular monitoring of liver and kidney function, viral load, and immune indicators to ensure both efficacy and safety. Long-term follow-up results show that most patients can maintain good viral suppression and have stable tolerance.

In addition, Bikeren Prenol Tablets have been included in multiple international guidelines and recommended as the first-line treatment option based on its long-term safety and convenience. Patients should avoid stopping medication at will or missing doses during long-term medication, otherwise it may lead to viral rebound or drug resistance. At the same time, patients with chronic kidney disease, hepatitis and co-infection, or who are taking other drugs still need to follow the doctor's evaluation to avoid drug interactions.

Reference materials:https://www.biktarvy.com/